Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05544929 · ClinicalTrials.gov registry record · Phase 1
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
A Phase 1 study of Carcinoma, Non-Small Cell Lung and Mesothelioma, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 1
- Development phase
- 126
- Enrollment target
- 19
- Study locations
NCT05544929: Active Phase 1 study of Carcinoma, Non-Small Cell Lung and Mesothelioma, sponsored by Novartis Pharmaceuticals.
NCT05544929 is a Phase 1 study of Carcinoma, Non-Small Cell Lung and Mesothelioma that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 126 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (61% lower). The trial reports 19 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05544929, a Phase 1 study of Carcinoma, Non-Small Cell Lung and Mesothelioma, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 126 participants
- Enrollment target
- 19
- Study locations
Study Summary
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or recommended dose.
Primary Outcome
A DLT is defined as an adverse event or abnormal laboratory value that occurs during the DLT evaluation period where the relationship to study treatment cannot be ruled out, and is not primarily related to disease, disease progression, intercurrent illness, or concomitant medications and meets the criteria defined in the study protocol
Conditions Studied
Interventions
- DRUG pembrolizumab
- DRUG KFA115
Study Locations (19)
Other
- Novartis Investigative Site - Beijing
- Novartis Investigative Site - Lyon
- Novartis Investigative Site - Essen
- Novartis Investigative Site - Hong Kong
- Novartis Investigative Site - Singapore
- Novartis Investigative Site - Seoul
- Novartis Investigative Site - Taipei
Massachusetts
- Massachusetts General Hospital . - Boston
- Massachusetts General Hospital - Boston
New York
- NYU School of Medicine - New York
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Tennessee
- SCRI Oncology Partners - Nashville
Ontario
- Novartis Investigative Site - Toronto
Guangdong
- Novartis Investigative Site - Guangzhou
Saxony
- Novartis Investigative Site - Dresden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2022-10-26 |
| Est. Completion | 2027-09-01 |
| Phase | Phase 1 |
What the registry record for NCT05544929 still lists
NCT05544929 is an interventional study that assigns participants to a tested intervention. The registered 126 participants enrollment target is mid-sized for trials with a published cap, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (61% lower).
The record links to 10 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 2 interventions - of which pembrolizumab is the first listed.
NCT05544929 lists 19 locations in 12 states (Other, Massachusetts, New York).
Frequently Asked Questions
What is clinical trial NCT05544929 about?
NCT05544929 is a clinical study titled "A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers". The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or recommended dose.
What is the current status of trial NCT05544929?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 126 participants. The study started on 2022-10-26. Estimated completion is 2027-09-01.
What conditions does trial NCT05544929 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Mesothelioma, Carcinoma, Renal Cell, Cutaneous Melanoma, Anal Cancer.
What interventions are being tested in trial NCT05544929?
The interventions under investigation include: pembrolizumab (DRUG), KFA115 (DRUG).
Who is sponsoring clinical trial NCT05544929?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05544929 being conducted?
This trial has 19 study locations across Massachusetts, New York, Pennsylvania, Tennessee, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05544929's enrollment target sits among peer trials
126 65th of 130 higher than 65 of 130 other Carcinoma, Non-Small Cell Lung trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
RECRUITING · Phase 1
-
A Study of LY4175408 in Participants With Advanced Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01873131 · 126 participants · NA
A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn
- NCT02621645 · 126 participants · Phase 4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
- NCT03838107 · 126 participants
Markers of Trajectory in Pediatric CRPS
- NCT03906422 · 126 participants · NA
Comparison of Patient-reported Pain After Initial Archwire Placement
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI